Loading…
Loading…
PRAX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PRAX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PRAX and 80,000+ other tickers.
See exactly how PRAX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PRAX and 80,000+ other tickers.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to…
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, sixteen have given a buy rating and four have given a
Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 581487 shares traded. The stock had previously closed at $366.81. Analyst Upgrades and Downgrades Several analysts recently weighed
Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,840 shares of the company's stock, valued at approximately $3,294,000. Several other hedge funds have also recently
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.